Critical advances and translational bottlenecks of gut microbiota-gut-brain axis targeted therapy for neurodegenerative and neurodevelopmental disorders.
Abstract
Neurological diseases have become a major global public health burden. Existing central nervous system-targeted therapies can only alleviate clinical symptoms but fail to halt the progression of neurodegenerative diseases, presenting mechanistic limitations and therapeutic bottlenecks. The gut microbiota participates in the regulation of central nervous system (CNS) homeostasis and neuropathological processes via the microbiota-gut-brain axis (MGBA). Notably, dysbiosis may induce damage to the blood-brain barrier, neurotransmitter dysregulation, and immune imbalance, thereby mediating the onset and progression of various neurological diseases, including Parkinson's disease, Alzheimer's disease (AD), autism spectrum disorder (ASD), and multiple sclerosis (MS). This article provides a systematic review of the core mechanisms by which the gut microbiome regulates neurological diseases, including inflammation regulation, oxidative stress responses, and neuroendocrine remodeling mediated by microbial metabolites. It also comprehensively summarizes the research progress, application advantages, and existing limitations of novel gut-targeted interventions, such as probiotics, prebiotics, fecal microbiota transplantation (FMT), dietary interventions, and live biological therapies. At the same time, the article critically examines key bottlenecks prevalent in the field: the causal relationship between the microbiota and disease remains unclear; there is a significant translational gap between animal and human studies; there is a lack of unified standards for multi-omics analysis systems; and interference from confounding factors such as age, diet, and medications is significant. Existing research indicates that gut microbiota interventions complement traditional symptomatic treatments and hold promising prospects for early disease intervention and adjunctive therapy for refractory patients. Future efforts should integrate multi-omics and artificial intelligence technologies to decipher the causal networks governing gut-central nervous system regulation, establish standardized research frameworks, advance the clinical translation of precision gut microbiota therapies, and provide new approaches for the comprehensive prevention, control, and personalized treatment of neurological disorders.